Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert Bourla says the company is betting big on cancer breakthroughs. He also voiced a personal belief that cures for many cancers could arrive within his lifetime, signaling a bold research push after the COVID-19 boom.
The drugmaker, which generated record sales during the pandemic, is now refocusing on one of medicine’s hardest problems. The strategy comes as investors and patients watch to see whether pandemic gains can translate into lasting health advances.
What Bourla Said
The bulk of the company’s COVID-era revenue is being used for cancer research, and Bourla thinks the cure for many cancers will be discovered in his lifetime.
The statement reflects both confidence and urgency. It also raises questions about what “cure” means across different cancer types, and how soon new therapies might reach patients.
From Pandemic Windfall to Oncology Bet
Pfizer’s COVID-19 vaccine and antiviral helped deliver historic sales in 2021 and 2022. While demand has cooled since, executives have framed those years as a springboard for long-term research spending. The company has already reshaped its pipeline around oncology and immunology.
A major part of that shift is dealmaking. Pfizer completed the acquisition of Seagen in late 2023 for roughly $43 billion, expanding its portfolio of antibody-drug conjugates, a drug class designed to deliver targeted chemotherapy to tumors. The move signaled an intent to grow in cancers where standard treatments still fall short.
Research budgets also reflect the pivot. Pfizer’s annual research and development spending has hovered in the low-to-mid teens in billions of dollars in recent years, and management has guided to higher investment in oncology programs. The company has stated that returns will depend on late-stage trials over the next several years.
- Seagen acquisition value: about $43 billion.
- Pfizer 2022 revenue: about $100 billion, driven by COVID products.
- R&D spend: typically more than $10 billion annually, with growth in oncology.
What Counts as a “Cure” in Cancer
Experts caution that cancer is not a single disease. Some cancers are curable today through surgery, radiation, or drugs, especially when found early. Others are managed as chronic conditions with targeted therapies and immunotherapy that extend life but do not eliminate the disease.
Progress often comes in increments. Five-year survival has improved for several cancers, including some blood cancers and melanoma, due to new treatments. But pancreatic, glioblastoma, and certain metastatic cases remain stubborn. Even when tumors go undetectable, relapse can occur years later.
Oncology researchers often talk about “functional cures,” where patients live long, cancer-free lives after treatment, even if a few cells remain. Bourla’s forecast appears to lean on this idea, rather than a single universal cure. The key will be how many cancers fall into that category and how soon.
Pipeline, Platforms, and Timelines
The next wave of approaches includes antibody-drug conjugates, cell therapies, bispecific antibodies, and personalized vaccines. Several drugmakers, including Pfizer’s partner BioNTech, are testing mRNA-based cancer vaccines designed to train the immune system to target tumor-specific mutations.
These studies take time. Many require long follow-up to confirm durability of response. Safety also matters, since powerful immune therapies can trigger serious side effects. Regulators will ask for clear evidence that new methods beat current standards.
Analysts say the first wins are likely in cancers where there is a clear target and strong early signals, such as certain breast, lung, and blood cancers. Tougher solid tumors may demand combinations of modalities and new biomarkers to guide care.
Investor, Patient, and System Impact
For investors, the question is whether oncology gains can offset the sharp decline in COVID product sales. Pfizer has guided to a reset in revenue in 2024, with an expected return to growth as new launches and oncology deals mature.
Patients and health systems face a different challenge: access. Advanced cancer drugs often launch with high prices. Policymakers in the United States and Europe are pressing for cost controls and value-based payment, especially as cancer care becomes more personalized.
Competition is intense. Major rivals, including Merck, Bristol Myers Squibb, Roche, AstraZeneca, and others, have deep pipelines and established oncology franchises. Collaboration, including trial partnerships and data sharing, could speed progress, but it also raises strategic and pricing questions.
What to Watch Next
Key signals will come from late-stage readouts in breast, lung, and hematologic cancers; integration of Seagen programs; and any early data from mRNA or other personalized vaccine trials. Safety profiles, durability of response, and quality-of-life outcomes will shape approvals and uptake.
Expanded screening and earlier detection tools may also boost the impact of new drugs. Catching cancers sooner often improves outcomes, even with existing treatments.
Bourla’s statement sets a high bar for Pfizer’s oncology ambitions. The company has the cash, the pipeline, and the dealmaking to advance the effort, but timelines are uncertain. The next few years will show whether pandemic gains can translate into longer lives for patients and whether “many cancers” can move from deadly to manageable—or even cured—in practice.
